Clinical Utility of Tremelimumab/Durvalumab as First-line Treatment for Unresectable Hepatocellular Carcinoma: Serum Cytokine Profile Insights
A history of Ate/Bev therapy increased soluble MHC class I and sPD-L1 serum levels. Tre/Dur therapy may be useful as a first-line treatment for uHCC, and elevated sPD-L1 levels may attenuate Dur efficacy. This increase may impair tumor recognition and potentially reduce Tre/Dur therapy effectiveness despite activated cytotoxic T cells.
Authors
- Kojiro Kobayashi (ORCID: https://orcid.org/0000-0001-6356-1671)
- Koichi Momiyama (ORCID: https://orcid.org/0000-0002-4438-7521)
- Hideki Nagumo
- Noritaka Wakui (ORCID: https://orcid.org/0000-0002-9957-8210)
- Kunihide Mohri (ORCID: https://orcid.org/0000-0001-9534-6132)
- Koji Higai (ORCID: https://orcid.org/0000-0003-3870-396X)
- Naoyuki Yoshimine (ORCID: https://orcid.org/0000-0003-4778-5856)
- Y Igarashi
- Hidenari Nagai (ORCID: https://orcid.org/0000-0001-8802-4936)
- Takanori Mukozu (ORCID: https://orcid.org/0000-0002-6716-2413)
- Yu Ogino
- TEPPEI MATSUI
- TAKAHISA MATSUDA
Institutions
- Toho University (JP)
- Tokyo Yamate Medical Center (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2026-02-27
- DOI
- https://doi.org/10.21873/anticanres.18049
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 0.00